pp-130 Concentrate for solution for infusion
Dossier type
CTD
Dossier status
Under development
Country of origin
Israel
GMP approvals
Israel
Comments
Indication: Platinum-resistant ovarian cancer; evaluation in combination with checkpoint inhibitors
Clinical stage: Phase 2 — COMPASSION-02 trial (COM701 + nivolumab) ongoing
Modality: Biologic (humanised IgG4 monoclonal antibody)
Mechanism / Target: Anti-PVRIG antibody — blocks PVRIG/PVRL2 inhibitory checkpoint axis on T and NK cells; restores anti-tumour immune response; complementary to PD-1 blockade
Route / form: Intravenous infusion
Differentiation: First-in-class PVRIG antagonist; computationally discovered target; potential synergy with PD-1 inhibitors in immunologically cold tumours
Manufacturer #39166
Computational biology-driven oncology company developing novel immune checkpoint inhibitors. Employs AI/genomics platform to discover previously unrecognised immunological targets. Wholly owned differentiated pipeline focused on solid tumours with unmet need.
None